nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—P2RY12—coronary artery disease	0.332	1	CbGaD
Epoprostenol—P2RY12—Ticagrelor—coronary artery disease	0.228	0.526	CbGbCtD
Epoprostenol—P2RY12—Clopidogrel—coronary artery disease	0.141	0.325	CbGbCtD
Epoprostenol—CYP2C9—Fenofibrate—coronary artery disease	0.00988	0.0229	CbGbCtD
Epoprostenol—CYP2C9—Gemfibrozil—coronary artery disease	0.0079	0.0183	CbGbCtD
Epoprostenol—CYP2C9—Clopidogrel—coronary artery disease	0.00685	0.0158	CbGbCtD
Epoprostenol—PTGIR—pulmonary artery—coronary artery disease	0.00617	0.167	CbGeAlD
Epoprostenol—CYP2C9—Pitavastatin—coronary artery disease	0.00599	0.0138	CbGbCtD
Epoprostenol—CYP2C9—Valsartan—coronary artery disease	0.00583	0.0135	CbGbCtD
Epoprostenol—CYP2C9—cardial valve—coronary artery disease	0.00545	0.147	CbGeAlD
Epoprostenol—CYP2C9—Rosuvastatin—coronary artery disease	0.00441	0.0102	CbGbCtD
Epoprostenol—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.0043	0.00995	CbGbCtD
Epoprostenol—CYP2C9—Simvastatin—coronary artery disease	0.0041	0.00949	CbGbCtD
Epoprostenol—CYP2C9—Pravastatin—coronary artery disease	0.00402	0.00929	CbGbCtD
Epoprostenol—CYP2C9—Lovastatin—coronary artery disease	0.00402	0.00929	CbGbCtD
Epoprostenol—PTGIS—artery—coronary artery disease	0.00398	0.108	CbGeAlD
Epoprostenol—CYP2C9—Atorvastatin—coronary artery disease	0.00366	0.00846	CbGbCtD
Epoprostenol—P2RY12—artery—coronary artery disease	0.00358	0.0968	CbGeAlD
Epoprostenol—PTGIS—endothelium—coronary artery disease	0.00336	0.0908	CbGeAlD
Epoprostenol—CYP2C9—Losartan—coronary artery disease	0.00335	0.00774	CbGbCtD
Epoprostenol—PTGIR—artery—coronary artery disease	0.00229	0.0618	CbGeAlD
Epoprostenol—PTGIS—myocardium—coronary artery disease	0.0021	0.0567	CbGeAlD
Epoprostenol—PTGIR—endothelium—coronary artery disease	0.00193	0.0522	CbGeAlD
Epoprostenol—Treprostinil—P2RY12—coronary artery disease	0.00177	1	CrCbGaD
Epoprostenol—PTGIS—heart—coronary artery disease	0.00147	0.0396	CbGeAlD
Epoprostenol—PTGIS—cardiovascular system—coronary artery disease	0.00138	0.0374	CbGeAlD
Epoprostenol—P2RY12—cardiovascular system—coronary artery disease	0.00125	0.0337	CbGeAlD
Epoprostenol—P2RY12—blood—coronary artery disease	0.000985	0.0266	CbGeAlD
Epoprostenol—PTGIR—heart—coronary artery disease	0.000842	0.0227	CbGeAlD
Epoprostenol—PTGIR—cardiovascular system—coronary artery disease	0.000795	0.0215	CbGeAlD
Epoprostenol—PTGIR—blood—coronary artery disease	0.000628	0.017	CbGeAlD
Epoprostenol—CYP2C9—heart—coronary artery disease	0.000301	0.00813	CbGeAlD
Epoprostenol—CYP2C9—cardiovascular system—coronary artery disease	0.000284	0.00767	CbGeAlD
Epoprostenol—CYP2C9—blood—coronary artery disease	0.000225	0.00607	CbGeAlD
Epoprostenol—Abdominal pain—Captopril—coronary artery disease	4.32e-05	0.000369	CcSEcCtD
Epoprostenol—Body temperature increased—Captopril—coronary artery disease	4.32e-05	0.000369	CcSEcCtD
Epoprostenol—Dizziness—Simvastatin—coronary artery disease	4.3e-05	0.000368	CcSEcCtD
Epoprostenol—Rash—Ezetimibe—coronary artery disease	4.3e-05	0.000368	CcSEcCtD
Epoprostenol—Dermatitis—Ezetimibe—coronary artery disease	4.3e-05	0.000367	CcSEcCtD
Epoprostenol—Confusional state—Ramipril—coronary artery disease	4.3e-05	0.000367	CcSEcCtD
Epoprostenol—Asthenia—Niacin—coronary artery disease	4.29e-05	0.000366	CcSEcCtD
Epoprostenol—Fatigue—Losartan—coronary artery disease	4.29e-05	0.000366	CcSEcCtD
Epoprostenol—Headache—Ezetimibe—coronary artery disease	4.28e-05	0.000365	CcSEcCtD
Epoprostenol—Oedema—Ramipril—coronary artery disease	4.26e-05	0.000364	CcSEcCtD
Epoprostenol—Anaphylactic shock—Ramipril—coronary artery disease	4.26e-05	0.000364	CcSEcCtD
Epoprostenol—Dry mouth—Timolol—coronary artery disease	4.25e-05	0.000363	CcSEcCtD
Epoprostenol—Pain—Losartan—coronary artery disease	4.25e-05	0.000363	CcSEcCtD
Epoprostenol—Constipation—Losartan—coronary artery disease	4.25e-05	0.000363	CcSEcCtD
Epoprostenol—Syncope—Lisinopril—coronary artery disease	4.25e-05	0.000363	CcSEcCtD
Epoprostenol—Vomiting—Eplerenone—coronary artery disease	4.25e-05	0.000363	CcSEcCtD
Epoprostenol—Nausea—Fenofibrate—coronary artery disease	4.23e-05	0.000362	CcSEcCtD
Epoprostenol—Pruritus—Niacin—coronary artery disease	4.23e-05	0.000361	CcSEcCtD
Epoprostenol—Asthenia—Pravastatin—coronary artery disease	4.22e-05	0.000361	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Furosemide—coronary artery disease	4.21e-05	0.00036	CcSEcCtD
Epoprostenol—Rash—Eplerenone—coronary artery disease	4.21e-05	0.00036	CcSEcCtD
Epoprostenol—Urticaria—Perindopril—coronary artery disease	4.21e-05	0.00036	CcSEcCtD
Epoprostenol—Hypersensitivity—Trandolapril—coronary artery disease	4.21e-05	0.00036	CcSEcCtD
Epoprostenol—Dermatitis—Eplerenone—coronary artery disease	4.21e-05	0.000359	CcSEcCtD
Epoprostenol—Diarrhoea—Valsartan—coronary artery disease	4.21e-05	0.000359	CcSEcCtD
Epoprostenol—Confusional state—Timolol—coronary artery disease	4.2e-05	0.000359	CcSEcCtD
Epoprostenol—Shock—Ramipril—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Hypersensitivity—Enalapril—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Body temperature increased—Perindopril—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Abdominal pain—Perindopril—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Palpitations—Lisinopril—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Diarrhoea—Olmesartan—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Headache—Eplerenone—coronary artery disease	4.19e-05	0.000358	CcSEcCtD
Epoprostenol—Nervous system disorder—Ramipril—coronary artery disease	4.18e-05	0.000357	CcSEcCtD
Epoprostenol—Thrombocytopenia—Ramipril—coronary artery disease	4.17e-05	0.000357	CcSEcCtD
Epoprostenol—Anaphylactic shock—Timolol—coronary artery disease	4.17e-05	0.000356	CcSEcCtD
Epoprostenol—Oedema—Timolol—coronary artery disease	4.17e-05	0.000356	CcSEcCtD
Epoprostenol—Pruritus—Pravastatin—coronary artery disease	4.16e-05	0.000356	CcSEcCtD
Epoprostenol—Loss of consciousness—Lisinopril—coronary artery disease	4.16e-05	0.000356	CcSEcCtD
Epoprostenol—Nausea—Clopidogrel—coronary artery disease	4.16e-05	0.000355	CcSEcCtD
Epoprostenol—Tachycardia—Ramipril—coronary artery disease	4.16e-05	0.000355	CcSEcCtD
Epoprostenol—Skin disorder—Ramipril—coronary artery disease	4.14e-05	0.000354	CcSEcCtD
Epoprostenol—Infection—Timolol—coronary artery disease	4.14e-05	0.000354	CcSEcCtD
Epoprostenol—Vomiting—Simvastatin—coronary artery disease	4.14e-05	0.000354	CcSEcCtD
Epoprostenol—Hypersensitivity—Telmisartan—coronary artery disease	4.14e-05	0.000353	CcSEcCtD
Epoprostenol—Cough—Lisinopril—coronary artery disease	4.13e-05	0.000353	CcSEcCtD
Epoprostenol—Nausea—Lovastatin—coronary artery disease	4.13e-05	0.000353	CcSEcCtD
Epoprostenol—Hyperhidrosis—Ramipril—coronary artery disease	4.12e-05	0.000352	CcSEcCtD
Epoprostenol—Rash—Simvastatin—coronary artery disease	4.1e-05	0.000351	CcSEcCtD
Epoprostenol—Dermatitis—Simvastatin—coronary artery disease	4.1e-05	0.00035	CcSEcCtD
Epoprostenol—Asthenia—Trandolapril—coronary artery disease	4.1e-05	0.00035	CcSEcCtD
Epoprostenol—Shock—Timolol—coronary artery disease	4.1e-05	0.00035	CcSEcCtD
Epoprostenol—Urticaria—Furosemide—coronary artery disease	4.09e-05	0.00035	CcSEcCtD
Epoprostenol—Diarrhoea—Niacin—coronary artery disease	4.09e-05	0.000349	CcSEcCtD
Epoprostenol—Nervous system disorder—Timolol—coronary artery disease	4.09e-05	0.000349	CcSEcCtD
Epoprostenol—Asthenia—Enalapril—coronary artery disease	4.08e-05	0.000349	CcSEcCtD
Epoprostenol—Headache—Simvastatin—coronary artery disease	4.08e-05	0.000348	CcSEcCtD
Epoprostenol—Abdominal pain—Furosemide—coronary artery disease	4.07e-05	0.000348	CcSEcCtD
Epoprostenol—Body temperature increased—Furosemide—coronary artery disease	4.07e-05	0.000348	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Losartan—coronary artery disease	4.07e-05	0.000347	CcSEcCtD
Epoprostenol—Dizziness—Valsartan—coronary artery disease	4.07e-05	0.000347	CcSEcCtD
Epoprostenol—Anorexia—Ramipril—coronary artery disease	4.06e-05	0.000347	CcSEcCtD
Epoprostenol—Nausea—Ezetimibe—coronary artery disease	4.05e-05	0.000346	CcSEcCtD
Epoprostenol—Skin disorder—Timolol—coronary artery disease	4.05e-05	0.000346	CcSEcCtD
Epoprostenol—Dizziness—Olmesartan—coronary artery disease	4.05e-05	0.000346	CcSEcCtD
Epoprostenol—Pruritus—Trandolapril—coronary artery disease	4.04e-05	0.000345	CcSEcCtD
Epoprostenol—Myalgia—Lisinopril—coronary artery disease	4.03e-05	0.000345	CcSEcCtD
Epoprostenol—Chest pain—Lisinopril—coronary artery disease	4.03e-05	0.000345	CcSEcCtD
Epoprostenol—Arthralgia—Lisinopril—coronary artery disease	4.03e-05	0.000345	CcSEcCtD
Epoprostenol—Hyperhidrosis—Timolol—coronary artery disease	4.03e-05	0.000344	CcSEcCtD
Epoprostenol—Asthenia—Telmisartan—coronary artery disease	4.03e-05	0.000344	CcSEcCtD
Epoprostenol—Pruritus—Enalapril—coronary artery disease	4.03e-05	0.000344	CcSEcCtD
Epoprostenol—Diarrhoea—Pravastatin—coronary artery disease	4.03e-05	0.000344	CcSEcCtD
Epoprostenol—Anxiety—Lisinopril—coronary artery disease	4.02e-05	0.000343	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	4.01e-05	0.000342	CcSEcCtD
Epoprostenol—Hypotension—Ramipril—coronary artery disease	3.98e-05	0.00034	CcSEcCtD
Epoprostenol—Anorexia—Timolol—coronary artery disease	3.97e-05	0.000339	CcSEcCtD
Epoprostenol—Pruritus—Telmisartan—coronary artery disease	3.97e-05	0.000339	CcSEcCtD
Epoprostenol—Nausea—Eplerenone—coronary artery disease	3.97e-05	0.000339	CcSEcCtD
Epoprostenol—Dizziness—Niacin—coronary artery disease	3.95e-05	0.000338	CcSEcCtD
Epoprostenol—Urticaria—Losartan—coronary artery disease	3.95e-05	0.000337	CcSEcCtD
Epoprostenol—Dry mouth—Lisinopril—coronary artery disease	3.94e-05	0.000337	CcSEcCtD
Epoprostenol—Body temperature increased—Losartan—coronary artery disease	3.93e-05	0.000336	CcSEcCtD
Epoprostenol—Abdominal pain—Losartan—coronary artery disease	3.93e-05	0.000336	CcSEcCtD
Epoprostenol—Asthenia—Captopril—coronary artery disease	3.92e-05	0.000335	CcSEcCtD
Epoprostenol—Diarrhoea—Trandolapril—coronary artery disease	3.91e-05	0.000334	CcSEcCtD
Epoprostenol—Vomiting—Valsartan—coronary artery disease	3.91e-05	0.000334	CcSEcCtD
Epoprostenol—Confusional state—Lisinopril—coronary artery disease	3.9e-05	0.000333	CcSEcCtD
Epoprostenol—Diarrhoea—Enalapril—coronary artery disease	3.89e-05	0.000333	CcSEcCtD
Epoprostenol—Hypotension—Timolol—coronary artery disease	3.89e-05	0.000333	CcSEcCtD
Epoprostenol—Dizziness—Pravastatin—coronary artery disease	3.89e-05	0.000332	CcSEcCtD
Epoprostenol—Vomiting—Olmesartan—coronary artery disease	3.89e-05	0.000332	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Ramipril—coronary artery disease	3.88e-05	0.000332	CcSEcCtD
Epoprostenol—Rash—Valsartan—coronary artery disease	3.88e-05	0.000331	CcSEcCtD
Epoprostenol—Dermatitis—Valsartan—coronary artery disease	3.87e-05	0.000331	CcSEcCtD
Epoprostenol—Nausea—Simvastatin—coronary artery disease	3.87e-05	0.00033	CcSEcCtD
Epoprostenol—Anaphylactic shock—Lisinopril—coronary artery disease	3.87e-05	0.00033	CcSEcCtD
Epoprostenol—Oedema—Lisinopril—coronary artery disease	3.87e-05	0.00033	CcSEcCtD
Epoprostenol—Pruritus—Captopril—coronary artery disease	3.86e-05	0.00033	CcSEcCtD
Epoprostenol—Rash—Olmesartan—coronary artery disease	3.86e-05	0.000329	CcSEcCtD
Epoprostenol—Insomnia—Ramipril—coronary artery disease	3.86e-05	0.000329	CcSEcCtD
Epoprostenol—Dermatitis—Olmesartan—coronary artery disease	3.85e-05	0.000329	CcSEcCtD
Epoprostenol—Headache—Valsartan—coronary artery disease	3.85e-05	0.000329	CcSEcCtD
Epoprostenol—Diarrhoea—Telmisartan—coronary artery disease	3.84e-05	0.000328	CcSEcCtD
Epoprostenol—Infection—Lisinopril—coronary artery disease	3.84e-05	0.000328	CcSEcCtD
Epoprostenol—Headache—Olmesartan—coronary artery disease	3.83e-05	0.000327	CcSEcCtD
Epoprostenol—Paraesthesia—Ramipril—coronary artery disease	3.83e-05	0.000327	CcSEcCtD
Epoprostenol—Shock—Lisinopril—coronary artery disease	3.8e-05	0.000325	CcSEcCtD
Epoprostenol—Asthenia—Perindopril—coronary artery disease	3.8e-05	0.000325	CcSEcCtD
Epoprostenol—Dyspnoea—Ramipril—coronary artery disease	3.8e-05	0.000325	CcSEcCtD
Epoprostenol—Vomiting—Niacin—coronary artery disease	3.8e-05	0.000325	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Timolol—coronary artery disease	3.8e-05	0.000324	CcSEcCtD
Epoprostenol—Hypersensitivity—Furosemide—coronary artery disease	3.8e-05	0.000324	CcSEcCtD
Epoprostenol—Somnolence—Ramipril—coronary artery disease	3.79e-05	0.000324	CcSEcCtD
Epoprostenol—Thrombocytopenia—Lisinopril—coronary artery disease	3.79e-05	0.000323	CcSEcCtD
Epoprostenol—Dizziness—Trandolapril—coronary artery disease	3.78e-05	0.000323	CcSEcCtD
Epoprostenol—Tachycardia—Lisinopril—coronary artery disease	3.77e-05	0.000322	CcSEcCtD
Epoprostenol—Insomnia—Timolol—coronary artery disease	3.77e-05	0.000322	CcSEcCtD
Epoprostenol—Rash—Niacin—coronary artery disease	3.77e-05	0.000322	CcSEcCtD
Epoprostenol—Dermatitis—Niacin—coronary artery disease	3.77e-05	0.000322	CcSEcCtD
Epoprostenol—Dizziness—Enalapril—coronary artery disease	3.76e-05	0.000322	CcSEcCtD
Epoprostenol—Skin disorder—Lisinopril—coronary artery disease	3.76e-05	0.000321	CcSEcCtD
Epoprostenol—Dyspepsia—Ramipril—coronary artery disease	3.75e-05	0.000321	CcSEcCtD
Epoprostenol—Pruritus—Perindopril—coronary artery disease	3.75e-05	0.00032	CcSEcCtD
Epoprostenol—Headache—Niacin—coronary artery disease	3.74e-05	0.00032	CcSEcCtD
Epoprostenol—Paraesthesia—Timolol—coronary artery disease	3.74e-05	0.00032	CcSEcCtD
Epoprostenol—Vomiting—Pravastatin—coronary artery disease	3.74e-05	0.00032	CcSEcCtD
Epoprostenol—Hyperhidrosis—Lisinopril—coronary artery disease	3.74e-05	0.000319	CcSEcCtD
Epoprostenol—Diarrhoea—Captopril—coronary artery disease	3.74e-05	0.000319	CcSEcCtD
Epoprostenol—Dyspnoea—Timolol—coronary artery disease	3.72e-05	0.000317	CcSEcCtD
Epoprostenol—Dizziness—Telmisartan—coronary artery disease	3.71e-05	0.000317	CcSEcCtD
Epoprostenol—Rash—Pravastatin—coronary artery disease	3.71e-05	0.000317	CcSEcCtD
Epoprostenol—Dermatitis—Pravastatin—coronary artery disease	3.71e-05	0.000317	CcSEcCtD
Epoprostenol—Decreased appetite—Ramipril—coronary artery disease	3.71e-05	0.000317	CcSEcCtD
Epoprostenol—Somnolence—Timolol—coronary artery disease	3.71e-05	0.000316	CcSEcCtD
Epoprostenol—Asthenia—Furosemide—coronary artery disease	3.7e-05	0.000316	CcSEcCtD
Epoprostenol—Headache—Pravastatin—coronary artery disease	3.69e-05	0.000315	CcSEcCtD
Epoprostenol—Anorexia—Lisinopril—coronary artery disease	3.69e-05	0.000315	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Ramipril—coronary artery disease	3.68e-05	0.000314	CcSEcCtD
Epoprostenol—Fatigue—Ramipril—coronary artery disease	3.68e-05	0.000314	CcSEcCtD
Epoprostenol—Dyspepsia—Timolol—coronary artery disease	3.67e-05	0.000313	CcSEcCtD
Epoprostenol—Hypersensitivity—Losartan—coronary artery disease	3.66e-05	0.000313	CcSEcCtD
Epoprostenol—Nausea—Valsartan—coronary artery disease	3.65e-05	0.000312	CcSEcCtD
Epoprostenol—Pruritus—Furosemide—coronary artery disease	3.65e-05	0.000311	CcSEcCtD
Epoprostenol—Constipation—Ramipril—coronary artery disease	3.65e-05	0.000311	CcSEcCtD
Epoprostenol—Nausea—Olmesartan—coronary artery disease	3.63e-05	0.00031	CcSEcCtD
Epoprostenol—Vomiting—Trandolapril—coronary artery disease	3.63e-05	0.00031	CcSEcCtD
Epoprostenol—Diarrhoea—Perindopril—coronary artery disease	3.63e-05	0.00031	CcSEcCtD
Epoprostenol—Decreased appetite—Timolol—coronary artery disease	3.62e-05	0.000309	CcSEcCtD
Epoprostenol—Vomiting—Enalapril—coronary artery disease	3.62e-05	0.000309	CcSEcCtD
Epoprostenol—Hypotension—Lisinopril—coronary artery disease	3.61e-05	0.000309	CcSEcCtD
Epoprostenol—Dizziness—Captopril—coronary artery disease	3.61e-05	0.000308	CcSEcCtD
Epoprostenol—Rash—Trandolapril—coronary artery disease	3.6e-05	0.000308	CcSEcCtD
Epoprostenol—Dermatitis—Trandolapril—coronary artery disease	3.6e-05	0.000308	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Timolol—coronary artery disease	3.6e-05	0.000307	CcSEcCtD
Epoprostenol—Fatigue—Timolol—coronary artery disease	3.59e-05	0.000307	CcSEcCtD
Epoprostenol—Rash—Enalapril—coronary artery disease	3.59e-05	0.000307	CcSEcCtD
Epoprostenol—Dermatitis—Enalapril—coronary artery disease	3.59e-05	0.000306	CcSEcCtD
Epoprostenol—Headache—Trandolapril—coronary artery disease	3.58e-05	0.000306	CcSEcCtD
Epoprostenol—Vomiting—Telmisartan—coronary artery disease	3.57e-05	0.000305	CcSEcCtD
Epoprostenol—Asthenia—Losartan—coronary artery disease	3.57e-05	0.000305	CcSEcCtD
Epoprostenol—Headache—Enalapril—coronary artery disease	3.57e-05	0.000305	CcSEcCtD
Epoprostenol—Pain—Timolol—coronary artery disease	3.56e-05	0.000304	CcSEcCtD
Epoprostenol—Nausea—Niacin—coronary artery disease	3.55e-05	0.000303	CcSEcCtD
Epoprostenol—Rash—Telmisartan—coronary artery disease	3.54e-05	0.000302	CcSEcCtD
Epoprostenol—Dermatitis—Telmisartan—coronary artery disease	3.54e-05	0.000302	CcSEcCtD
Epoprostenol—Diarrhoea—Furosemide—coronary artery disease	3.53e-05	0.000301	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Lisinopril—coronary artery disease	3.52e-05	0.000301	CcSEcCtD
Epoprostenol—Pruritus—Losartan—coronary artery disease	3.52e-05	0.0003	CcSEcCtD
Epoprostenol—Headache—Telmisartan—coronary artery disease	3.52e-05	0.0003	CcSEcCtD
Epoprostenol—Dizziness—Perindopril—coronary artery disease	3.51e-05	0.000299	CcSEcCtD
Epoprostenol—Insomnia—Lisinopril—coronary artery disease	3.5e-05	0.000299	CcSEcCtD
Epoprostenol—Nausea—Pravastatin—coronary artery disease	3.5e-05	0.000299	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Ramipril—coronary artery disease	3.49e-05	0.000298	CcSEcCtD
Epoprostenol—Paraesthesia—Lisinopril—coronary artery disease	3.47e-05	0.000297	CcSEcCtD
Epoprostenol—Vomiting—Captopril—coronary artery disease	3.47e-05	0.000297	CcSEcCtD
Epoprostenol—Dyspnoea—Lisinopril—coronary artery disease	3.45e-05	0.000294	CcSEcCtD
Epoprostenol—Rash—Captopril—coronary artery disease	3.44e-05	0.000294	CcSEcCtD
Epoprostenol—Dermatitis—Captopril—coronary artery disease	3.44e-05	0.000294	CcSEcCtD
Epoprostenol—Somnolence—Lisinopril—coronary artery disease	3.44e-05	0.000294	CcSEcCtD
Epoprostenol—Headache—Captopril—coronary artery disease	3.42e-05	0.000292	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Timolol—coronary artery disease	3.41e-05	0.000291	CcSEcCtD
Epoprostenol—Dizziness—Furosemide—coronary artery disease	3.41e-05	0.000291	CcSEcCtD
Epoprostenol—Dyspepsia—Lisinopril—coronary artery disease	3.4e-05	0.000291	CcSEcCtD
Epoprostenol—Diarrhoea—Losartan—coronary artery disease	3.4e-05	0.000291	CcSEcCtD
Epoprostenol—Nausea—Trandolapril—coronary artery disease	3.39e-05	0.00029	CcSEcCtD
Epoprostenol—Urticaria—Ramipril—coronary artery disease	3.39e-05	0.000289	CcSEcCtD
Epoprostenol—Nausea—Enalapril—coronary artery disease	3.38e-05	0.000289	CcSEcCtD
Epoprostenol—Vomiting—Perindopril—coronary artery disease	3.37e-05	0.000288	CcSEcCtD
Epoprostenol—Abdominal pain—Ramipril—coronary artery disease	3.37e-05	0.000288	CcSEcCtD
Epoprostenol—Body temperature increased—Ramipril—coronary artery disease	3.37e-05	0.000288	CcSEcCtD
Epoprostenol—Decreased appetite—Lisinopril—coronary artery disease	3.36e-05	0.000287	CcSEcCtD
Epoprostenol—Rash—Perindopril—coronary artery disease	3.34e-05	0.000285	CcSEcCtD
Epoprostenol—Dermatitis—Perindopril—coronary artery disease	3.34e-05	0.000285	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Lisinopril—coronary artery disease	3.34e-05	0.000285	CcSEcCtD
Epoprostenol—Nausea—Telmisartan—coronary artery disease	3.33e-05	0.000285	CcSEcCtD
Epoprostenol—Fatigue—Lisinopril—coronary artery disease	3.33e-05	0.000285	CcSEcCtD
Epoprostenol—Headache—Perindopril—coronary artery disease	3.32e-05	0.000284	CcSEcCtD
Epoprostenol—Urticaria—Timolol—coronary artery disease	3.31e-05	0.000283	CcSEcCtD
Epoprostenol—Pain—Lisinopril—coronary artery disease	3.31e-05	0.000282	CcSEcCtD
Epoprostenol—Constipation—Lisinopril—coronary artery disease	3.31e-05	0.000282	CcSEcCtD
Epoprostenol—Body temperature increased—Timolol—coronary artery disease	3.29e-05	0.000281	CcSEcCtD
Epoprostenol—Abdominal pain—Timolol—coronary artery disease	3.29e-05	0.000281	CcSEcCtD
Epoprostenol—Dizziness—Losartan—coronary artery disease	3.29e-05	0.000281	CcSEcCtD
Epoprostenol—Vomiting—Furosemide—coronary artery disease	3.28e-05	0.00028	CcSEcCtD
Epoprostenol—Rash—Furosemide—coronary artery disease	3.25e-05	0.000278	CcSEcCtD
Epoprostenol—Dermatitis—Furosemide—coronary artery disease	3.25e-05	0.000277	CcSEcCtD
Epoprostenol—Nausea—Captopril—coronary artery disease	3.24e-05	0.000277	CcSEcCtD
Epoprostenol—Headache—Furosemide—coronary artery disease	3.23e-05	0.000276	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Lisinopril—coronary artery disease	3.16e-05	0.00027	CcSEcCtD
Epoprostenol—Vomiting—Losartan—coronary artery disease	3.16e-05	0.00027	CcSEcCtD
Epoprostenol—Nausea—Perindopril—coronary artery disease	3.15e-05	0.000269	CcSEcCtD
Epoprostenol—Hypersensitivity—Ramipril—coronary artery disease	3.14e-05	0.000268	CcSEcCtD
Epoprostenol—Rash—Losartan—coronary artery disease	3.13e-05	0.000268	CcSEcCtD
Epoprostenol—Dermatitis—Losartan—coronary artery disease	3.13e-05	0.000268	CcSEcCtD
Epoprostenol—Headache—Losartan—coronary artery disease	3.11e-05	0.000266	CcSEcCtD
Epoprostenol—Urticaria—Lisinopril—coronary artery disease	3.07e-05	0.000262	CcSEcCtD
Epoprostenol—Hypersensitivity—Timolol—coronary artery disease	3.07e-05	0.000262	CcSEcCtD
Epoprostenol—Nausea—Furosemide—coronary artery disease	3.06e-05	0.000261	CcSEcCtD
Epoprostenol—Asthenia—Ramipril—coronary artery disease	3.06e-05	0.000261	CcSEcCtD
Epoprostenol—Abdominal pain—Lisinopril—coronary artery disease	3.06e-05	0.000261	CcSEcCtD
Epoprostenol—Body temperature increased—Lisinopril—coronary artery disease	3.06e-05	0.000261	CcSEcCtD
Epoprostenol—Pruritus—Ramipril—coronary artery disease	3.02e-05	0.000258	CcSEcCtD
Epoprostenol—Asthenia—Timolol—coronary artery disease	2.99e-05	0.000255	CcSEcCtD
Epoprostenol—Nausea—Losartan—coronary artery disease	2.95e-05	0.000252	CcSEcCtD
Epoprostenol—Pruritus—Timolol—coronary artery disease	2.95e-05	0.000252	CcSEcCtD
Epoprostenol—Diarrhoea—Ramipril—coronary artery disease	2.92e-05	0.000249	CcSEcCtD
Epoprostenol—Diarrhoea—Timolol—coronary artery disease	2.85e-05	0.000244	CcSEcCtD
Epoprostenol—Hypersensitivity—Lisinopril—coronary artery disease	2.85e-05	0.000243	CcSEcCtD
Epoprostenol—Dizziness—Ramipril—coronary artery disease	2.82e-05	0.000241	CcSEcCtD
Epoprostenol—Asthenia—Lisinopril—coronary artery disease	2.77e-05	0.000237	CcSEcCtD
Epoprostenol—Dizziness—Timolol—coronary artery disease	2.76e-05	0.000235	CcSEcCtD
Epoprostenol—Pruritus—Lisinopril—coronary artery disease	2.74e-05	0.000234	CcSEcCtD
Epoprostenol—Vomiting—Ramipril—coronary artery disease	2.71e-05	0.000232	CcSEcCtD
Epoprostenol—Rash—Ramipril—coronary artery disease	2.69e-05	0.00023	CcSEcCtD
Epoprostenol—Dermatitis—Ramipril—coronary artery disease	2.69e-05	0.000229	CcSEcCtD
Epoprostenol—Headache—Ramipril—coronary artery disease	2.67e-05	0.000228	CcSEcCtD
Epoprostenol—Vomiting—Timolol—coronary artery disease	2.65e-05	0.000226	CcSEcCtD
Epoprostenol—Diarrhoea—Lisinopril—coronary artery disease	2.65e-05	0.000226	CcSEcCtD
Epoprostenol—Rash—Timolol—coronary artery disease	2.63e-05	0.000224	CcSEcCtD
Epoprostenol—Dermatitis—Timolol—coronary artery disease	2.63e-05	0.000224	CcSEcCtD
Epoprostenol—Headache—Timolol—coronary artery disease	2.61e-05	0.000223	CcSEcCtD
Epoprostenol—Dizziness—Lisinopril—coronary artery disease	2.56e-05	0.000218	CcSEcCtD
Epoprostenol—Nausea—Ramipril—coronary artery disease	2.53e-05	0.000216	CcSEcCtD
Epoprostenol—Nausea—Timolol—coronary artery disease	2.48e-05	0.000211	CcSEcCtD
Epoprostenol—Vomiting—Lisinopril—coronary artery disease	2.46e-05	0.00021	CcSEcCtD
Epoprostenol—Rash—Lisinopril—coronary artery disease	2.44e-05	0.000208	CcSEcCtD
Epoprostenol—Dermatitis—Lisinopril—coronary artery disease	2.44e-05	0.000208	CcSEcCtD
Epoprostenol—Headache—Lisinopril—coronary artery disease	2.42e-05	0.000207	CcSEcCtD
Epoprostenol—Nausea—Lisinopril—coronary artery disease	2.3e-05	0.000196	CcSEcCtD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—coronary artery disease	6.53e-06	8.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—coronary artery disease	6.53e-06	8.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—coronary artery disease	6.53e-06	8.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ITGB3—coronary artery disease	6.49e-06	8.17e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ITGB3—coronary artery disease	6.49e-06	8.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—coronary artery disease	6.49e-06	8.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—coronary artery disease	6.45e-06	8.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AK1—coronary artery disease	6.38e-06	8.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCH1—coronary artery disease	6.38e-06	8.03e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—coronary artery disease	6.34e-06	7.98e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—coronary artery disease	6.34e-06	7.98e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—coronary artery disease	6.31e-06	7.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PPP2CA—coronary artery disease	6.31e-06	7.94e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PPP2CA—coronary artery disease	6.31e-06	7.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CETP—coronary artery disease	6.3e-06	7.93e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—coronary artery disease	6.27e-06	7.9e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AGT—coronary artery disease	6.25e-06	7.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—coronary artery disease	6.23e-06	7.84e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—coronary artery disease	6.22e-06	7.83e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKCD—coronary artery disease	6.2e-06	7.8e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PRKCD—coronary artery disease	6.2e-06	7.8e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—coronary artery disease	6.13e-06	7.71e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—coronary artery disease	6.13e-06	7.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UGCG—coronary artery disease	6.11e-06	7.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MDH2—coronary artery disease	6.11e-06	7.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPAT—coronary artery disease	6.11e-06	7.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCD1—coronary artery disease	6.11e-06	7.69e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HTR2A—coronary artery disease	6.06e-06	7.63e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HTR2A—coronary artery disease	6.06e-06	7.63e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOA1—coronary artery disease	6.05e-06	7.62e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—C3—coronary artery disease	6.05e-06	7.62e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—C3—coronary artery disease	6.05e-06	7.62e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—coronary artery disease	6e-06	7.55e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK14—coronary artery disease	5.96e-06	7.5e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PGM1—coronary artery disease	5.88e-06	7.41e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—coronary artery disease	5.85e-06	7.36e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—F2—coronary artery disease	5.78e-06	7.27e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FN1—coronary artery disease	5.78e-06	7.27e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—coronary artery disease	5.77e-06	7.27e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—coronary artery disease	5.77e-06	7.27e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6ST—coronary artery disease	5.75e-06	7.24e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AGT—coronary artery disease	5.75e-06	7.24e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AGT—coronary artery disease	5.75e-06	7.24e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—coronary artery disease	5.75e-06	7.24e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—coronary artery disease	5.73e-06	7.21e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKBIA—coronary artery disease	5.71e-06	7.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—coronary artery disease	5.7e-06	7.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PYGB—coronary artery disease	5.68e-06	7.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CKB—coronary artery disease	5.68e-06	7.15e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—coronary artery disease	5.64e-06	7.09e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—coronary artery disease	5.64e-06	7.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—coronary artery disease	5.64e-06	7.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—coronary artery disease	5.64e-06	7.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOA1—coronary artery disease	5.57e-06	7.01e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOA1—coronary artery disease	5.57e-06	7.01e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—coronary artery disease	5.53e-06	6.96e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—coronary artery disease	5.52e-06	6.95e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—coronary artery disease	5.52e-06	6.95e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK14—coronary artery disease	5.49e-06	6.9e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK14—coronary artery disease	5.49e-06	6.9e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—coronary artery disease	5.45e-06	6.86e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—coronary artery disease	5.38e-06	6.77e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—coronary artery disease	5.38e-06	6.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DLAT—coronary artery disease	5.34e-06	6.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM2—coronary artery disease	5.34e-06	6.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLIN1—coronary artery disease	5.34e-06	6.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PFKFB3—coronary artery disease	5.34e-06	6.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COX5B—coronary artery disease	5.34e-06	6.73e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—coronary artery disease	5.34e-06	6.72e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FN1—coronary artery disease	5.32e-06	6.69e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—F2—coronary artery disease	5.32e-06	6.69e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FN1—coronary artery disease	5.32e-06	6.69e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—F2—coronary artery disease	5.32e-06	6.69e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GSK3B—coronary artery disease	5.3e-06	6.68e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6ST—coronary artery disease	5.29e-06	6.66e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6ST—coronary artery disease	5.29e-06	6.66e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—POMC—coronary artery disease	5.26e-06	6.62e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CREB1—coronary artery disease	5.26e-06	6.62e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKBIA—coronary artery disease	5.25e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKBIA—coronary artery disease	5.25e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL2—coronary artery disease	5.15e-06	6.48e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6R—coronary artery disease	5.13e-06	6.46e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—coronary artery disease	5.09e-06	6.4e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—coronary artery disease	5.09e-06	6.4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—coronary artery disease	5.08e-06	6.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT1E1—coronary artery disease	5.07e-06	6.38e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—coronary artery disease	5.06e-06	6.37e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—coronary artery disease	5.04e-06	6.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—coronary artery disease	4.92e-06	6.19e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GSK3B—coronary artery disease	4.88e-06	6.14e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GSK3B—coronary artery disease	4.88e-06	6.14e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—POMC—coronary artery disease	4.84e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—POMC—coronary artery disease	4.84e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CREB1—coronary artery disease	4.84e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CREB1—coronary artery disease	4.84e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HK2—coronary artery disease	4.83e-06	6.08e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1B1—coronary artery disease	4.83e-06	6.08e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—coronary artery disease	4.81e-06	6.06e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—coronary artery disease	4.81e-06	6.05e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL2—coronary artery disease	4.74e-06	5.96e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL2—coronary artery disease	4.74e-06	5.96e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6R—coronary artery disease	4.72e-06	5.94e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6R—coronary artery disease	4.72e-06	5.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—coronary artery disease	4.66e-06	5.86e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—coronary artery disease	4.66e-06	5.86e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGF2—coronary artery disease	4.65e-06	5.86e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—coronary artery disease	4.64e-06	5.83e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—coronary artery disease	4.64e-06	5.83e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—coronary artery disease	4.64e-06	5.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC27A1—coronary artery disease	4.63e-06	5.83e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—coronary artery disease	4.59e-06	5.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LCAT—coronary artery disease	4.54e-06	5.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CPT1B—coronary artery disease	4.54e-06	5.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA4—coronary artery disease	4.46e-06	5.61e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JAK2—coronary artery disease	4.46e-06	5.61e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—coronary artery disease	4.43e-06	5.57e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—coronary artery disease	4.43e-06	5.57e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—coronary artery disease	4.42e-06	5.57e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—coronary artery disease	4.42e-06	5.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—coronary artery disease	4.38e-06	5.51e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—coronary artery disease	4.37e-06	5.5e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PDHA1—coronary artery disease	4.31e-06	5.42e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCLM—coronary artery disease	4.31e-06	5.42e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGF2—coronary artery disease	4.28e-06	5.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGF2—coronary artery disease	4.28e-06	5.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—coronary artery disease	4.22e-06	5.31e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—coronary artery disease	4.22e-06	5.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOB—coronary artery disease	4.18e-06	5.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TXNRD1—coronary artery disease	4.17e-06	5.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP11B2—coronary artery disease	4.17e-06	5.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC22A3—coronary artery disease	4.11e-06	5.17e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—coronary artery disease	4.11e-06	5.17e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JAK2—coronary artery disease	4.1e-06	5.17e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JAK2—coronary artery disease	4.1e-06	5.17e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—coronary artery disease	4.07e-06	5.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ARNTL—coronary artery disease	4.05e-06	5.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HADH—coronary artery disease	4.05e-06	5.1e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—coronary artery disease	4.02e-06	5.06e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—coronary artery disease	4.02e-06	5.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LPL—coronary artery disease	3.99e-06	5.02e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—coronary artery disease	3.93e-06	4.95e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—coronary artery disease	3.9e-06	4.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—coronary artery disease	3.89e-06	4.9e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—coronary artery disease	3.88e-06	4.89e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—coronary artery disease	3.87e-06	4.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G2A—coronary artery disease	3.84e-06	4.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA2—coronary artery disease	3.84e-06	4.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX2—coronary artery disease	3.84e-06	4.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT1A1—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX4—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HK1—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG5—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—coronary artery disease	3.79e-06	4.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HADHA—coronary artery disease	3.75e-06	4.72e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—coronary artery disease	3.75e-06	4.71e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—coronary artery disease	3.75e-06	4.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA1—coronary artery disease	3.7e-06	4.66e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—coronary artery disease	3.68e-06	4.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPA—coronary artery disease	3.66e-06	4.61e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—coronary artery disease	3.62e-06	4.55e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—coronary artery disease	3.62e-06	4.55e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—coronary artery disease	3.59e-06	4.51e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—coronary artery disease	3.59e-06	4.51e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—coronary artery disease	3.57e-06	4.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—coronary artery disease	3.56e-06	4.48e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—coronary artery disease	3.56e-06	4.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCB3—coronary artery disease	3.55e-06	4.46e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA5—coronary artery disease	3.51e-06	4.42e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—coronary artery disease	3.49e-06	4.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—coronary artery disease	3.49e-06	4.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—P4HB—coronary artery disease	3.44e-06	4.33e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	3.41e-06	4.29e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—coronary artery disease	3.39e-06	4.26e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—coronary artery disease	3.39e-06	4.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G1B—coronary artery disease	3.38e-06	4.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	3.34e-06	4.21e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—coronary artery disease	3.31e-06	4.16e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	3.3e-06	4.16e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—coronary artery disease	3.29e-06	4.14e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—coronary artery disease	3.29e-06	4.14e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—VCAN—coronary artery disease	3.19e-06	4.01e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—coronary artery disease	3.17e-06	3.99e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOA—coronary artery disease	3.16e-06	3.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DCN—coronary artery disease	3.07e-06	3.86e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—coronary artery disease	3.04e-06	3.83e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—coronary artery disease	3.04e-06	3.83e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—coronary artery disease	3.03e-06	3.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH2—coronary artery disease	2.99e-06	3.76e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—coronary artery disease	2.98e-06	3.74e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	2.91e-06	3.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3C2A—coronary artery disease	2.91e-06	3.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LIPC—coronary artery disease	2.91e-06	3.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2C19—coronary artery disease	2.91e-06	3.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HBA1—coronary artery disease	2.91e-06	3.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOC3—coronary artery disease	2.89e-06	3.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDLR—coronary artery disease	2.87e-06	3.62e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	2.87e-06	3.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—coronary artery disease	2.84e-06	3.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC9A1—coronary artery disease	2.84e-06	3.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCLC—coronary artery disease	2.81e-06	3.53e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CETP—coronary artery disease	2.81e-06	3.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—coronary artery disease	2.79e-06	3.51e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—coronary artery disease	2.79e-06	3.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SDC1—coronary artery disease	2.78e-06	3.49e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—coronary artery disease	2.74e-06	3.45e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—coronary artery disease	2.74e-06	3.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMB5—coronary artery disease	2.62e-06	3.3e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMA6—coronary artery disease	2.62e-06	3.3e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	2.62e-06	3.29e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—coronary artery disease	2.58e-06	3.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CTGF—coronary artery disease	2.56e-06	3.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMGCR—coronary artery disease	2.54e-06	3.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GOT2—coronary artery disease	2.54e-06	3.19e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—coronary artery disease	2.38e-06	2.99e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—coronary artery disease	2.38e-06	2.99e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCB1—coronary artery disease	2.33e-06	2.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	2.29e-06	2.88e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—coronary artery disease	2.29e-06	2.88e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCA1—coronary artery disease	2.26e-06	2.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GOT1—coronary artery disease	2.19e-06	2.76e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GGT1—coronary artery disease	2.19e-06	2.76e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—coronary artery disease	2.11e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—coronary artery disease	2.1e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—coronary artery disease	2.1e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—coronary artery disease	1.97e-06	2.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	1.95e-06	2.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—coronary artery disease	1.94e-06	2.44e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—coronary artery disease	1.94e-06	2.44e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—coronary artery disease	1.94e-06	2.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAT—coronary artery disease	1.92e-06	2.41e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOB—coronary artery disease	1.86e-06	2.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—coronary artery disease	1.81e-06	2.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPL—coronary artery disease	1.78e-06	2.23e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—coronary artery disease	1.73e-06	2.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CD36—coronary artery disease	1.69e-06	2.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP2CA—coronary artery disease	1.67e-06	2.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—coronary artery disease	1.6e-06	2.01e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AGT—coronary artery disease	1.52e-06	1.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—coronary artery disease	1.49e-06	1.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA1—coronary artery disease	1.47e-06	1.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.41e-06	1.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—coronary artery disease	1.3e-06	1.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POMC—coronary artery disease	1.28e-06	1.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—coronary artery disease	1.17e-06	1.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—coronary artery disease	1.11e-06	1.4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—coronary artery disease	1.02e-06	1.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—coronary artery disease	6.27e-07	7.9e-06	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—coronary artery disease	5.13e-07	6.45e-06	CbGpPWpGaD
